Anakinra: Timely Targeted Anticytokine Therapy for Severe COVID-19

Among patients with elevated soluble urokinase plasminogen receptor levels, standard care plus anakinra increased full recovery and lowered mortality compared with standard care alone. Identifying patients at excess risk for severe COVID-19 is critical for devising treatment strategies (particularly those involving immune modulation) where early therapy is important. One predictor […]

Read More

Antithrombotic Therapy Not Warranted in COVID-19 Outpatients

Antithrombotic therapy in clinically stable, nonhospitalized COVID-19 patients does not offer protection against adverse cardiovascular or pulmonary events, new randomized clinical trial results suggest. Antithrombotic therapy has proven useful in acutely ill inpatients with COVID-19, but in this study, treatment with aspirin or apixaban (Eliquis) did not reduce the rate of all-cause mortality, symptomatic […]

Read More